Partners
Avectas has exclusively licenced from ONK Therapeutics (ONK) a Chimeric Antigen Receptor-directed Natural Killer (CAR NK) cell therapy incorporating ONK’s proprietary Death Receptor (DR5) TRAIL variant for the treatment of B-cell malignancies. Under the collaboration, ONK will be responsible for rapidly progressing the potential therapy to a Phase I clinical trial. The potential therapy will be engineered using Avectas’ proprietary non-viral cell engineering platform (SOLUPORE®). Avectas will retain worldwide development and commercialization rights to the therapy. Read More
Avectas has entered into a collaborative agreement with The Simon Laboratory at UC Davis, California, USA (UCD) to engage in the characterisation of cells engineered with Avectas’ proprietary, non-viral SOLUPORE® cell engineering platform. Under the collaboration, The Simon Laboratory at UCD will characterise cells engineered using SOLUPORE®, leveraging UCD’s unique cell membrane characterisation expertise and assays. Read More
Avectas and Vycellix, an immuno-discovery cell & gene therapy company have collaborated to advance next-generation solutions for the optimized manufacture of Cell & Gene Therapies. The companies will collaborate on the delivery of Vycellix’s novel RNA immunomodulator VY-M using Avectas’ cell engineering platform, SOLUPORE®. The collaboration will address current limitations for cell-based therapies, in particular with respect to the need to accelerate the manufacturing process, reduce the cost of manufacture, and ultimately improve patient outcomes. Read More
Avectas has joined the new Competence Center for Next Generation NK Cell-based Cancer Immunotherapy (“NextGenNK”) as a collaborative partner established at Karolinska Institutet (“KI”), Stockholm, Sweden. NextGenNK is scheduled to receive up to approximately $12 million in funding over the next five years from multiple stakeholders including Vinnova, Karolinska Institutet and its industry partners with the opportunity to apply for extended funding for an additional five years at a similar level. Read More
Avectas secured €2.1 million funding under the European Union’s Horizon 2020 programme. Avectas is developing a technology that temporarily makes permeable cells extracted from a patient and allows them to be re-engineered to attack cancers before being infused back into patients. Read More
Avectas and CCRM, a leader in developing and commercializing cell and gene therapies, have entered into a collaboration to accelerate the translation of Avectas’ non-viral cell engineering platform (SOLUPORE®) into the clinic. Combining Avectas’ novel cell engineering platform and CCRM’s experience in the development of manufacturing processes for cell therapies will accelerate the transfer of the SOLUPORE® technology to Avectas development partners. Read More
Become a Partner
Avectas’ SOLUPORE® platform offers a cell engineering solution for next generation cell and gene therapies. Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these lifesaving gene modified cell therapy products.
If you would like to learn more about working with Avectas and our cell engineering technology, get in touch with us.